Carregant...
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of...
Guardat en:
| Publicat a: | Arthritis Res Ther |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5655983/ https://ncbi.nlm.nih.gov/pubmed/29065909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1445-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|